This paper is in the following e-collection/theme issue:

Clinical Cancer Research (129) Drug Repurposing and Off-Label Use (30) Clinical Informatics (1393) Clinical Information and Decision Making (2027) Decision Support for Health Professionals (1603)

Published on in Vol 12 (2026)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/76908, first published .
Immunotherapy Safety in Thymic Epithelial Tumors: Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System

Immunotherapy Safety in Thymic Epithelial Tumors: Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System

Immunotherapy Safety in Thymic Epithelial Tumors: Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System

Authors of this article:

Ruilian Chen1, 2, 3 Author Orcid Image ;   Hanrui Chen1, 3 Author Orcid Image ;   Lingling Sun1, 3 Author Orcid Image ;   Yang Cao1, 3 Author Orcid Image ;   Lizhu Lin1, 3, 4 Author Orcid Image
Article Authors Cited by Tweetations Metrics

Ruilian Chen   1, 2, 3 , MD ;   Hanrui Chen   1, 3 , PhD ;   Lingling Sun   1, 3 , PhD ;   Yang Cao   1, 3 , PhD ;   Lizhu Lin   1, 3, 4 , PhD

1 Oncology Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China

2 The First Clinical Medical School of Guangzhou University of Chinese Medicine, Guangzhou, China

3 Guangdong Clinical Research Academy of Chinese Medicine, Guangzhou, China

4 Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou, China

Corresponding Author:

  • Lizhu Lin, PhD
  • Oncology Center
  • The First Affiliated Hospital of Guangzhou University of Chinese Medicine
  • 16 Jichang Road, Baiyun District
  • Guangzhou 510405
  • China
  • Phone: 86 020-36596360
  • Email: gzucmlinlz@163.com